Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 - a review

Autor: Christine M. Akamine, Hana M. El Sahly
Rok vydání: 2021
Předmět:
PAMPs
Pathogen-associated molecular patterns

COVID-19 Vaccines
MERS-CoV
Middle east respiratory syndrome coronavirus

CVnCOV
CureVac

VOC
Variants of concern

Review Article
BMI
Body mass index

COVID-NET
COVID-19-Associated Hospitalization Surveillance Network

DCs
Dendritic cells

EUA
Emergency use authorization

mRNA
Messenger ribonucleic acid

dsRNA
Double-stranded RNA

GMC
Geometric mean concentration

Physiology (medical)
SAM
Self-amplifying mRNA

COVID-19
Coronavirus disease of 2019

Humans
LNP
Liposomal nanoparticle

CDC
Centers for Disease Control

RNA
Messenger

Ad5
Adenovirus type 5

ACE-2
Angiotensin converting enzyme receptor

Pandemics
BNT162 Vaccine
B.1.1.7
Alpha variant

MHC
Major histocompatibility complex

Vaccines
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2

B.1.351
Beta variant

SARS-CoV-2
Biochemistry (medical)
Public Health
Environmental and Occupational Health

COVID-19
General Medicine
FDA
Food and Drug Administration

GMT
Geometric mean titer

BAU
binding antibody units

APCs
Antigen presenting cells

UTR
Untranslated regions

VAERS
Vaccine adverse event reporting system

RBD
Receptor-binding domain
Zdroj: Translational Research
ISSN: 1878-1810
Popis: The mRNA therapeutics have been studied since the 1970s and the currently available mRNA vaccines against COVID-19 are the culmination of decades of scientific research. The mRNA vaccines BNT162b2 and mRNA-1273 have played a key role in our global response to the COVID-19 pandemic as they have demonstrated significant advantages over conventional vaccines and have proven to be highly effective against COVID-19 associated hospitalization and severe illness in large clinical trials and studies using real-world data.
Databáze: OpenAIRE